JP2024504927A - 縮合四環式の化合物、組成物及びその使用 - Google Patents

縮合四環式の化合物、組成物及びその使用 Download PDF

Info

Publication number
JP2024504927A
JP2024504927A JP2023541723A JP2023541723A JP2024504927A JP 2024504927 A JP2024504927 A JP 2024504927A JP 2023541723 A JP2023541723 A JP 2023541723A JP 2023541723 A JP2023541723 A JP 2023541723A JP 2024504927 A JP2024504927 A JP 2024504927A
Authority
JP
Japan
Prior art keywords
compound
alkyl
compound according
optionally substituted
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023541723A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024504927A5 (https=
Inventor
セルラノ－ウー，マイケル，エイチ．
イエ，ジーシオン
ジョン，ウェイホン
Original Assignee
タボメデックス バイオサイエンシズ インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by タボメデックス バイオサイエンシズ インコーポレーテッド filed Critical タボメデックス バイオサイエンシズ インコーポレーテッド
Publication of JP2024504927A publication Critical patent/JP2024504927A/ja
Publication of JP2024504927A5 publication Critical patent/JP2024504927A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2023541723A 2021-01-11 2022-01-10 縮合四環式の化合物、組成物及びその使用 Pending JP2024504927A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/071062 2021-01-11
CN2021071062 2021-01-11
PCT/US2022/011824 WO2022150707A1 (en) 2021-01-11 2022-01-10 Fused quadracyclic compounds, compositions and uses thereof

Publications (2)

Publication Number Publication Date
JP2024504927A true JP2024504927A (ja) 2024-02-02
JP2024504927A5 JP2024504927A5 (https=) 2025-01-17

Family

ID=82356986

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023541723A Pending JP2024504927A (ja) 2021-01-11 2022-01-10 縮合四環式の化合物、組成物及びその使用

Country Status (11)

Country Link
US (1) US20240140958A1 (https=)
EP (1) EP4274833A4 (https=)
JP (1) JP2024504927A (https=)
KR (1) KR20230145335A (https=)
CN (1) CN118574834A (https=)
AU (1) AU2022205678A1 (https=)
BR (1) BR112023013722A2 (https=)
CA (1) CA3204167A1 (https=)
IL (1) IL304142A (https=)
MX (1) MX2023007992A (https=)
WO (1) WO2022150707A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA42543A (fr) 2015-07-30 2018-06-06 Modernatx Inc Arn épitope peptidiques concatémériques
WO2025219950A1 (en) 2024-04-18 2025-10-23 Astrazeneca Ab Small molecule cx3cr1 modulators

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019501971A (ja) * 2016-01-04 2019-01-24 タボメデックス バイオサイエンシズ，エルエルシー 縮合四環式の化合物、組成物及びその使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019501971A (ja) * 2016-01-04 2019-01-24 タボメデックス バイオサイエンシズ，エルエルシー 縮合四環式の化合物、組成物及びその使用

Also Published As

Publication number Publication date
CA3204167A1 (en) 2022-07-14
EP4274833A1 (en) 2023-11-15
IL304142A (en) 2023-09-01
MX2023007992A (es) 2023-09-27
CN118574834A (zh) 2024-08-30
AU2022205678A1 (en) 2023-08-03
BR112023013722A2 (pt) 2024-01-30
WO2022150707A1 (en) 2022-07-14
KR20230145335A (ko) 2023-10-17
EP4274833A4 (en) 2025-02-19
US20240140958A1 (en) 2024-05-02

Similar Documents

Publication Publication Date Title
US12459925B2 (en) Sulphonyl urea derivatives as NLRP3 inflammasome modulators
US10273239B2 (en) Spiro-lactam NMDA receptor modulators and uses thereof
CN107949559B (zh) 作为irak4调节剂的双环稠合杂芳基或芳基化合物
JP6153674B2 (ja) 細菌感染を治療するためのモノバクタム有機化合物
AU2010264027B9 (en) Novel azabicyclohexanes
CN113072542B (zh) RORγt抑制剂及其制备方法和用途
CN115298180B (zh) 治疗或抑制急性髓细胞白血病复发的化合物
HK1249509A1 (zh) 作为irak-4抑制剂的吲唑及氮杂吲唑化合物
US20160376307A1 (en) Iap antagonists
JP2023530268A (ja) Ｉｌ－１７の小分子モジュレーター
EP4284365A1 (en) Cdk2 inhibitors and methods of using the same
JP2024504927A (ja) 縮合四環式の化合物、組成物及びその使用
JP2023526839A (ja) アゼチジン環状尿素類
CN108602822A (zh) 含有7-氧代-6-(硫氧基)-1,6-二氮杂双环[3.2.1]辛烷-2-甲酰胺的化合物及其在治疗细菌感染中的用途
JP7774579B2 (ja) ピペラジン複素環アミド尿素類を含む受容体共役タンパク質１阻害剤
CN108779123A (zh) 稠合四环化合物、其组合物和用途
EA052066B1 (ru) Конденсированные четырехциклические соединения, их композиции и применение
EP4476225A1 (en) 3-substituted pyridazine compounds as smarca2 and/or smarca4 degraders
WO2020138499A1 (ja) アルキル置換化合物
HK40087766A (zh) 包括哌嗪杂环酰胺脲的受体-相互作用蛋白1抑制剂
HK40033410A (en) 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
NZ709870A (en) Spiro-lactam nmda receptor modulators and uses thereof

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20240213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260303